Do atypical antipsychotics really enhance smoking reduction more than typical ones?: The effects of antipsychotics on smoking reduction in patients with schizophrenia

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 319-328

  Wu, Bo Jian ^a   Chen, Hsing Kang ^a   Lee, Shin Min ^a  

^a Yuli Hospital   (Taiwan)

Author keywords

atypical antipsychotics; clozapine; nicotine replacement therapy; schizophrenia; smoking reduction

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; NICOTINE PATCH; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; DRUG MEGADOSE; FAGERSTROM TEST FOR NICOTINE DEPENDENCE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; SMOKING REDUCTION; TRANSDERMAL PATCH;

ADULT; ANTIPSYCHOTIC AGENTS; BUPROPION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NICOTINE; SCHIZOPHRENIA; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS;

EID: 84877585476     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828b2575     Document Type: Article

References (76)

1. Lyon ER. A review of the effects of nicotine on schizophrenia and antipsychotic medications. Psychiatr Serv. 1999; 50: 1346-1350.
2. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry. 2001; 42: 393-402.
3. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005; 76: 135-157.
4. Culhane MA, Schoenfeld DA, Barr RS, et al. Predictors of early abstinence in smokers with schizophrenia. J Clin Psychiatry. 2008; 69: 1743-1750.
5. Dolan SL, Sacco KA, Termine A, et al. Neuropsychological deficits are associated with smoking cessation treatment failure in patients with schizophrenia. Schizophr Res. 2004; 70: 263-275.
6. Berg SA, Chambers RA. Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropharmacology. 2008; 54: 1201-1207.
7. Chambers RA. A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J Dual Diagn. 2009; 5: 139-148.
8. Barnes M, Lawford BR, Burton SC, et al. Smoking and schizophrenia: is symptom profile related to smoking and which antipsychotic medication is of benefit in reducing cigarette use? Aust N Z J Psychiatry. 2006; 40: 575-580.
9. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. Smoking and schizophrenia. Psychiatr Danub. 2009; 21: 371-375.
10. Jabs BE, Bartsch AJ, Pfuhlmann B. Susceptibility to neuroleptic-induced parkinsonismVage and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry. 2003; 18: 177-181.
11. Leonard S, Adler LE, Benhammou K, et al. Smoking and mental illness. Pharmacol Biochem Behav. 2001; 70: 561-570.
12. Woznica AA, Sacco KA, George TP. Prepulse inhibition deficits in schizophrenia are modified by smoking status. Schizophr Res. 2009; 112: 86-90.
13. Corrigall WA. Understanding brain mechanisms in nicotine reinforcement. Br J Addict. 1991; 86: 507-510.
14. Lucksted A, Dixon LB, Sembly JB. A focus group pilot study of tobacco smoking among psychosocial rehabilitation clients. Psychiatr Serv. 2000; 51: 1544-1548.
15. Tidey JW, Rohsenow DJ. Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls. Schizophr Res. 2009; 115: 310-316
16. Silagy C, Mant D, Fowler G, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2000; 2.
17. Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006; 163: 1934-1942.
18. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000; 157: 1835-1842.
19. George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008; 63: 1092-1096.
20. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2010; CD007253.
21. Moss TG, Sacco KA, Allen TM, et al. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 2009; 104: 94-99.
22. Matthews AM, Wilson VB, Mitchell SH. The role of antipsychotics in smoking and smoking cessation. CNS Drugs. 2011; 25: 299-315.
23. George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002; 52: 53-61.
24. Procyshyn RM, Ihsan N, Thompson D. A comparison of smoking behaviours between patients treated with clozapine and depot neuroleptics. Int Clin Psychopharmacol. 2001; 16: 291-294.
25. Procyshyn RM, Tse G, Sin O, et al. Concomitant clozapine reduces smoking in patients treated with risperidone. Eur Neuropsychopharmacol. 2002; 12: 77-80.
26. Brauer LH, Cramblett MJ, Paxton DA, et al. Haloperidol reduces smoking of both nicotine-containing and denicotinized cigarettes. Psychopharmacology (Berl). 2001; 159: 31-37.
27. de Leon J, Diaz FJ, Josiassen RC, et al. Does clozapine decrease smoking? Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 757-762.
28. Barr AM, Procyshyn RM, Hui P, et al. Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophr Res. 2008; 100: 252-260.
29. McEvoy J, Freudenreich O, McGee M, et al. Clozapine decreases smoking in patients with chronic schizophrenia. Biol Psychiatry. 1995; 37: 550-552.
30. Combs DR, Advokat C. Antipsychotic medication and smoking prevalence in acutely hospitalized patients with chronic schizophrenia. Schizophr Res. 2000; 46: 129-137.
31. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry. 1999; 46: 125-129.
32. Kim SH, Han DH, Joo SY, et al. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol. 2010; 25: 187-190.
33. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27: 1159-1172.
34. Meltzer HY. What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol. 2004; 4: 53-57.
35. Meltzer HY. Atypical antipsychotic drugs have their merits. Lancet. 2009; 373: 1007; author reply 1007-1008.
36. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001; 158: 360-369.
37. Stahl SM. Stahl's Essential Psychopharmacology, Neuroscientific Basis and Practical Applications. 3rd ed. Cambridge, UK: Cambridge University Press; 2008.
38. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006; 20: 389-409.
39. Sadock BJ, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
40. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003; 60: 553-564.
41. Sadock BJ, Sadock VA, Ruiz P. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 9th ed. Philadelphia, PA: LippincottWilliams & Wilkins; 2009.
42. Gerlach J. New antipsychotics: classification, efficacy, and adverse effects. Schizophrenia Bull. 1991; 17: 289-309.
43. Lan TH, Chiu HJ, Wu BJ, et al. Readiness to quit and smoking reduction outcomes. Am J Psychiatry. 2007; 164: 827-828.
44. Tuan YC, Wu BJ, Lan TH, et al. Smoking cessation and reduction rate between nicotine replacement therapy and bupropion in chronic psychotic patients. The 46th Anniversary of the Taiwan Society of Psychiatry, Taiwan (Abstract). 2007
45. Arakawa R, Ito H, Okumura M, et al. Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2010; 260: 345-350.
46. Suzuki T. Does 'selective binding profile' result in 'selective treatment'? Nihon Shinkei Seishin Yakurigaku Zasshi. 2001; 21: 1-5.
47. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996; 14: 87-96.
48. Sim K, Su HC, Fujii S, et al. High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies. Br J Clin Pharmacol. 2009; 67: 110-117.
49. Dwyer DS, Donohoe D. Induction of hyperglycemia in mice with atypical antipsychotic drugs that inhibit glucose uptake. Pharmacol Biochem Behav. 2003; 75: 255-260.
50. Hrdlicka M, Zedkova I, Blatny M, et al. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuro Endocrinol Lett. 2009; 30: 256-261.
51. Ichikawa J, Dai J, O'Laughlin IA, et al. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 2002; 26: 325-339.
52. Wu RR, Zhao JP, Zhai JG, et al. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol. 2007; 27: 374-379.
53. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006; 63: 1079-1087.
54. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict. 1991; 86: 1119-1127.
55. Huang CL, Lin HH, Wang HH. The psychometric properties of the Chinese version of the Fagerstrom Test for Nicotine Dependence. Addict Behav. 2006; 31: 2324-2327.
56. Cheng JJ, Ho H, Chang CJ, et al. Positive and Negative Syndrome Scale (PANSS): establishment and reliability study of a Mandarin Chinese language version. Taiwan J Psychiatry. 1996; 10: 251-258.
57. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull. 1987; 13: 261-276.
58. Simpson G, Kunz-Bartholini E. Relationship of individual tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst. 1968; 29: 269-274.
59. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change. Applications to addictive behaviors. Am Psychol. 1992; 47: 1102-1114.
60. American Psychiatric Association. Practice Guidelines for the Treatment of Patients With Schizophrenia. Washington DC: American Psychiatric Press; 2004.
61. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003; 64: 663-667.
62. Dino G, Kamal K, Horn K, et al. Stage of change and smoking cessation outcomes among adolescents. Addict Behav. 2004; 29: 935-940.
63. Cohen J. Statistical Power Analysis for the Behavior Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc, Publishers; 1988.
64. Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. Addict Behav. 2012; 37: 11-24.
65. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010; 30: 417-424.
66. Mahler SV, de Wit H. Effects of haloperidol on reactions to smoking cues in humans. Behav Pharmacol. 2005; 16: 123-126.
67. Volkow ND, Fowler JS, Wang GJ, et al. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry. 2004; 9: 557-569.
68. Fehr C, Yakushev I, Hohmann N, et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry. 2008; 165: 507-514.
69. Schlagenhauf F, Juckel G, Koslowski M, et al. Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine. Psychopharmacology (Berl). 2008; 196: 673-684.
70. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124: 57-73.
71. Karamatskos E, Mulert C, Lambert M, et al. Subjective well-being of patient with schizophrenia as a target of drug treatment. Curr Pharmacol Biotechnol. 2012; 13: 1490-1499.
72. Caskey NH, Jarvik ME, Wirshing WC, et al. Modulating tobacco smoking rates by dopaminergic stimulation and blockade. Nicotine Tob Res. 2002; 4: 259-266.
73. Weiner DM, Meltzer HY, Veinbergs I, et al. The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology (Berl). 2004; 177: 207-216.
74. Chou KR, Chen R, Lee JF, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud. 2004; 41: 321-330.
75. Sreedharan J, Muttappallymyalil J, Venkatramana M. Nurses' attitude and practice in providing tobacco cessation care to patients. J Prev Med Hyg. 2010; 51: 57-61.
76. Evins AE, Cather C, Rigotti NA, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry. 2004; 65: 307-311.